Munich, August, 18th 2008

Curacyte AG announces that Dr. Andreas Zaby, CFO, will resign as of September 30, 2008. Dr. Zaby will be joining the faculty of the Berlin School of Economics as a professor of business administration as of Oct 1, 2008 where his teaching and research work will focus on both, the biopharmaceutical industry and entrepreneurial finance. Dr. Zaby will remain an active consultant to the industry.

His tasks at Curacyte AG are being transferred to Stephanie Pypetz, Curacyte’s VP of Finance & Accounting. Ms. Pypetz joined Curacyte in 2007 from GPC Biotech AG, Martinsried. Before joining GPC, she was an audit manager with Ernst & Young’s Munich office.

Dr. Helmut Giersiefen, Curacyte’s CEO, stated: „I would like to express my sincere thanks to Dr. Andreas Zaby for his valuable contributions as a fellow founder and as the CFO of Curacyte. During the last eight years, he has guided the company through several major financing rounds and M&A transactions. Thanks to his work, Curacyte stands out as a financially sound company ready to further advance and commercialize its late-stage R&D pipeline.“ Dr. Helmut Schühsler, Curacyte’s Chairman, commented: „The board thanks Dr. Zaby for many years of dedicated service to the company and wishes him well for his future endeavors.“

About Curacyte

Curacyte AG is an advanced biopharmaceutical company dedicated to the development of new therapeutics for acute and critical care conditions.

Curacyte’s lead product is hemoximer (Pyridoxalated Hemoglobin Polyoxyethylene, PHP). Hemoximer has been developed as a scavenger of nitric oxide, the causative agent responsible for vasodilation and hypotension in shock. The ability to scavenge and metabolize NO is one of the important physiological functions of natural hemoglobin. Hemoximer has been demonstrated to reverse the vasodilation and resolve the hypotension associated with distributive shock. Hemoximer has completed Phase II clinical development in its primary indication, distributive shock, and is now entering a Phase III study in catecholamine-resistant distributive shock. Apart from distributive shock, hemoximer is also being studied as an adjunct to high-dose interleukin 2 (IL-2) cancer therapy for patients with metastatic melanoma and renal cell carcinoma. Shock is a frequent dose-limiting side effect of high-dose IL-2 therapy. Hemoximer is the proposed International Non-Proprietary Name (INN) for PHP.
The Company’s website is www.curacyte.com.